Journal article
Relationship Between Urinary Phosphate and All-Cause and Cardiovascular Mortality in a National Population-Based Longitudinal Cohort Study
ND Toussaint, MJ Damasiewicz, SG Holt, ZX Lu, DJ Magliano, RC Atkins, SJ Chadban, JE Shaw, KR Polkinghorne
Journal of Renal Nutrition | W B SAUNDERS CO-ELSEVIER INC | Published : 2022
Abstract
Objectives: High dietary phosphate intake may lead to adverse outcomes including cardiovascular disease (CVD). Urinary phosphate excretion, a marker of intestinal phosphate absorption, may be a more reliable marker of phosphate homeostasis in steady state than serum phosphate. Studies report good agreement between urine phosphate-to-creatinine ratio (uPiCr) and 24-hour urinary phosphate; however, whether uPiCr is associated with increased risk of CVD or mortality remains uncertain. This study aimed to assess the relationship between uPiCr and all-cause and CVD mortality. Design and Methods: This is an observational longitudinal cohort study using data from the population-based national Austr..
View full abstractGrants
Awarded by GlaxoSmithKline
Funding Acknowledgements
The AusDiab study, initiated and coordinated by the International Diabetes Institute, and subsequently coordinated by the Baker Heart and Diabetes Institute, gratefully acknowledges the support and assistance given by K. Anstey, B. Atkins, B. Balkau, E. Barr, A. Cameron, S. Chad-ban, M. de Courten, D. Dunstan, A. Kavanagh, S. Murray, N. Owen, K. Polkinghorne, T. Welborn, P. Zimmet, and all the study participants. Also, for funding or logistical support, we are grateful to the National Health and Medical Research Council (NHMRC grants 233200 and 1007544) , Australian Government Department of Health and Ageing, Abbott Australasia Pty Ltd, Alphapharm Pty Ltd, Amgen Australia, Astra-Zeneca, Bristol-Myers Squibb, City Health Centre-Diabetes Service-Canberra, Department of Health and Community Services-Northern Territory, Department of Health and Human Services - Tasmania, Department of Health - New South Wales, Department of Health - Western Australia, Department of Health - South Australia, Department of Human Services - Victoria, Diabetes Australia, Diabetes Australia Northern Territory, Eli Lilly Australia, Estate of the Late Edward Wilson, GlaxoSmithKline, Jack Brockhoff Foundation, Janssen-Cilag, Kidney Health Australia, Marian & FH Flack Trust, Menzies Research Institute, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Phar-maceuticals, Pfizer Pty Ltd, Pratt Foundation, Queensland Health, Roche Diagnostics Australia, Royal Prince Alfred Hospital, Sydney, Sa-nofi Aventis, Sanofi-Synthelabo, and the Victorian Government's OIS Program. The authors would like to thank Monash Pathology for providing the technical support for the analysis of urinary phosphate levels in the Aus-Diab cohort.